DAOIB for the Treatment of Brain Fog
DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial
Chang Gung Memorial Hospital
40 participants
Feb 27, 2023
INTERVENTIONAL
Conditions
Summary
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
Eligibility
Inclusion Criteria3
- "post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments
- physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits
- have sufficient education to communicate effectively and are capable of completing the assessments of the study
Exclusion Criteria8
- history of significant cerebrovascular disease
- Hachinski Ischemic Score > 4
- major neurological, psychiatric or medical conditions other than long COVID-induced cognitive impairments
- memantine use (memantine is an NMDAR partial antagonist)
- substance (including alcohol) abuse or dependence
- delusion, hallucination or delirium symptoms
- severe visual or hearing loss
- inability to follow the protocol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05764538